TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #14906 · Jul 3

#typescript#ai#anthropic#artifacts#assistant_api#aws#azure#chatgpt#chatgpt_clone#claude#clone#dall_e_3#deepseek#gemini#google#librechat#o1#openai#plugins#vision#webui LibreChat is a free, open-source AI chatbot platform that lets you use many AI models like OpenAI, Anthropic, and AWS in one place. It offers advanced features such as secure code execution in multiple programming languages, AI assistants that can handle files and tools without coding, and the ability to generate images and diagrams directly in chat. You can search conversations easily, manage multiple chat threads, and customize the interface to fit your needs. LibreChat supports multiple languages, speech input/output, and secure multi-user access. It can be deployed locally or on the cloud, giving you flexibility and control over your AI experience. This means you get a powerful, customizable AI assistant without needing to pay for ChatGPT Plus or rely on a single provider[1][3][5]. https://github.com/danny-avila/LibreChat

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选
Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment